Particularly, the CD19IL15 CAR-NK product showed more effective tumor control as compared to NT-NK and CD19 CAR-NK cells, with tumor clearance by day 14 post-engraftment (Figure 2b), recapitulating the in vivo experiments. The gene discussed is CD19; the disease is neoplasm.